Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis.

BMC pulmonary medicine - 2 Jul 2024

Liu Yi, Yalavarthi Sindhu, Yang Fan, Abdul-Rashid Yusif, Tang Shenkun, Long Zihe, Qin Yongkai, Wu Kerui, Wang Zhifei

Abstract excerpt

BACKGROUND: Treatment of non-small lung cancer (NSCLC) has evolved in recent years, benefiting from advances in immunotherapy and targeted therapy. However, limited biomarkers exist to assist clinicians and patients in selecting the most effective, personalized treatment strategies. Targeted next-generation sequencing-based genomic profiling has become routine in cancer treatment and generated crucial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Immunotherapy

Share to Pemetrexed

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 38956553
DOI: 10.1186/s12890-024-03124-4
PMCID: PMC11218090

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis.PMID 38956553Read ↗

Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers.Semantic proximity Read ↗

Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancerSemantic proximity Read ↗

A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.Semantic proximity Read ↗

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.Semantic proximity Read ↗

Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.Semantic proximity Read ↗

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Semantic proximity Read ↗

TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC.Semantic proximity Read ↗

Extensive prediction of drug response in mutation-subtype-specific LUAD with machine learning approach.Semantic proximity Read ↗

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.Semantic proximity Read ↗

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancerSemantic proximity Read ↗

Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.